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The incidence of ectopic pregnancy is on the rise and accounts for 
approximately 2% of all pregnancies in the United States. Incidence has 
increase six-fold over the last two decades.! Ectopic pregnancy is the 
leading cause of maternal mortality in the United States in the first 
trimester, and accounted for thirty-five deaths in 1997.2 But beyond the 
medical implications of ectopic pregnancy, it also has ethical 
considerations that need to be taken into account. The Ethical and 
Religious Directives for Catholic Health Care Services states that: 
"Catholic health care ministry witnesses to the sanctity of human life 'from 
the moment of conception until death."'3 Yet in contrast to this, current 
medical practice for the treatment of ectopic pregnancy consists of 
modalities that could constitute a direct abortion. What is a Catholic 
physician or hospital to do in treating a woman with an ectopic pregnancy? 
How are we to be witnesses to the sanctity of life in this tragic problem? 
This presentation is intended to address the medical and ethical concerns in 
the treatment of ectopic pregnancy. 
Ectopic Pregnancy Defined 
An ectopic pregnancy is the implantation of the embryo outside of its 
normal intrauterine site. Subsequent growth of the embryo occurs for a 
variable length of time before the clinical signs and symptoms of an 
ectopic pregnancy become manifest, depending on the site of implantation. 
Sites of ectopic implantation are the fallopian tube (95-97%), insterstitiaV 
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cornual angle (2-4%), ovary (0.5 %), abdominal cavity (0.3%), or cervix 
(0.1 % ).4 Clinical signs and symptoms occur at about six to eight weeks 
after the last menstrual period in a tubal pregnancy and at ten to twelve 
weeks in an interstitial/cornual angle pregnancy. In the majority of cases of 
ectopic pregnancy, presenting symptoms are secondary to tubal rupture or 
tuballeaking.4 Abdominal ectopics can proceed to viability in 11 - 45% of 
cases, but maternal mortality from massive hemorrhage is not uncommon.5.6 
Etiology of ectopic pregnancy includes tubal damage secondary to 
pelvic inflammatory disease, intrauterine devices, progesterone-only pills, 
two or more elective abortions, ART, previous ectopic pregnancy, tubal 
scarring from any cause, and hormonal abnormalities. Evidence of pelvic 
inflammatory disease is present in up to 77% of fallopian tubes with an 
ectopic pregnancy.? 
Due to the advancement of the diagnostic studies available, the 
diagnosis of an ectopic pregnancy is made much earlier in its course than 
in years past, and has lead to a decline in maternal mortality.2 These 
diagnostic studies include sensitive ~-HCG assays, trans-vaginal 
ultrasound, progesterone assays, and laparoscopy. These diagnostic 
advancements have largely replaced the classic triad of pain, bleeding, and 
adnexal mass in the definitive diagnosis of ectopic gestation. 
The diagnosis of ectopic pregnancy is based upon the accurate 
detection of ~-HCG, a hormone produced by the syncytiotrophoblasts of 
the embryo. ~-HCG levels are detectable in the blood as early as six days 
after conception and are always present by twelve days after conception.s 
~-HCG levels approximately double every forty-eight hours in early 
pregnancy; an abnormal rise of ~-HCG is suggestive of miscarriage and 
ectopic pregnancy. 
At levels over 2000 mIU/ml, a gestational sac should be seen in the 
uterus by trans-vaginal ultrasound, although in cases of multiple gestation 
there can be a delay of visualization of the gestational sac.9 Progesterone 
levels are also useful predictors of normal intrauterine gestations, ectopic 
pregnancy, and spontaneous abortion, especially when used in conjunction 
with ~-HCG levels and trans-vaginal ultrasound. Progesterone level s <5 
ng/ml are highly suggestive of a miscarriage or ectopic pregnancy. 10 Trans-
vaginal ultrasound is a highly useful tool in the diagnosis of early 
intrauterine pregnancies, and when used in conjunction with ~-HCG 
levels, gives physicians the ability to often make the diagnosis of ectopic 
pregnancies without the need for laparoscopy or laparotomy. Intrauterine 
gestational sacs can be seen by trans-vaginal ultrasound as early as sixteen 
days post conception, II and embryonic cardiac activity can be seen shortly 
thereafter. 
Unlike years past, most cases of ectopic pregnancy today are 
diagnosed before tubal rupture has occurred, without the need for surgical 
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exploration to stop life-threatening bleeding. The early diagnosis has also 
lead to the trend to treat ectopic pregnancy by way of laparoscopy or with 
medication. Current treatment modalities for ectopic pregnancy are: 1) 
expectant management; 2) surgical management (salpingostomy or 
salpingectomy); 3) medical management (methotrexate). 
Expectant management is a sound option for early ectopic pregnancies 
that have relatively low ~-HCG levels. The ectopic tissue gradually 
degenerates over time and is eventually reabsorbed. Criteria for expectant 
management are: stable vital signs; ~-HCG levels less than 1,000-2,000 
mlU/ml and falling; mass size less than 2-4 centimeters; and less than 50 
ml of hemoperitoneum. 12.13 Successful resolution rates range from 60-64% 
if the above criteria are met. 12.13 If levels are above 2,000 mID/mI, the 
failure rate is 93.3%.13 Benefits are that the patient avoids any surgical or 
medical treatment with the inherent risks. Risks include tubal rupture and 
failure for spontaneous resolution and the need for further intervention. 
Three Types of Management 
The first type of surgical management is laparoscopic salpingostomy, 
which is now deemed the surgery of choice for the treatment of an 
unruptured ectopic pregnancy.14 A linear incision is made in the anti-
mesenteric portion of the fallopian tube, and the gestational tissue is 
removed. The tube is left open to heal by secondary intention, hopefully 
allowing tubal patency and function to be preserved. Future pregnancy 
rates are reported to be between 50 - 67%, but repeat ectopics occur about 
7 -16% of the time. IS Risks of linear salpingostomy are that trophoblastic 
ti ssue may be left behind leading to a condition of a "chronic ectopic ', 
where trophoblastic tissue continues to remain viable. A chronic ectopic 
occurs about 5-20% of the time following linear salpingostomy. IS 
The second type of surgical management is salpingectomy. Partial or 
total salpingectomy is still the procedure of choice in ruptured ectopic 
pregnancy.4.S Part or all of the tube is removed via the laparascope or 
laparotomy. Future pregnancy rates for patients undergoing salpingectomy 
depend on the condition of the remaining tube, and range between 30-
80%.1 5 There is no chance of persistent ectopic. Re-anastamosis of the tube 
may also be offered in patients who undergo a partial salpingectomy, either 
at the initial surgery or at a later time. 
The third type of management for ectopic is medical management, 
which involves the systemic injection of methotrexate. Methotrexate is an 
anti-metabolite, and its site of action is the rapidly dividing outer 
trophoblastic tissue of the embryo. After the trophoblastic tissue is 
eliminated, reabsorption of the tissue occurs and hopefully tubal patency 
and function are preserved. Toxicity of methotrexate can occur in 20-30% 
August, 2003 197 
of patients, depending on whether single or multiple dose regimens are 
used.4 Methotrexate fails to eliminate the ectopic pregnancy in 5-29% of 
cases. IS Failure is more likely to occur if cardiac activity is present, !)-HCG 
levels are >3,000-5,000 mIU/ml, and progesterone levels are >10 ng/ 
ml. I6,17,18 Patients who received systemic methotrexate therapy had a more 
negative impact on their quality of life (secondary to the side-effects of the 
medication) than did patients undergoing surgical management. 19 
Methotrexate therapy would be preferred by most patients, even with the 
negative side-effects, but only as part of a completely non-surgical 
management strategy,zo Future pregnancy rates following methotrexate are 
comparable to salpingostomy (50-67%). 
In the current management strategies for ectopic pregnancy, 
controversy still exists over the best treatment modality. Despite the push 
by many gynecologists for tube-sparing surgery (salpingostomy) or 
medical management (methotrexate) of ectopic pregnancy, these methods 
have not been shown to be superior to salpingectomy in terms of future 
pregnancy rates.21 
The condition of the contra-lateral tube and a history of previous 
tubal surgery are the most important factors in determining subsequent 
pregnancy rates, not the treatment modality chosen.22,23 If the contra-lateral 
fallopian tube was normal and there is no past history of tubal surgery, 
pregnancy rates are about 70%. If the contra-lateral fallopian tube is 
abnormal, the pregnancy rates are only 30-40%.22.23 One advantage of 
salpingectomy is that it avoids any potential of a chronic ectopic. In a 
patient with an ectopic pregnancy in her only remaining tube, however, 
tube-sparing surgery, methotrexate, or partial salpingectomy with re-
anastamosis (by surgeons with proper training) are the only options that 
allow for preservation of future fertility. An advantage of methotrexate is 
that it offers the patient a completely non-surgical intervention for ectopic 
pregnancy, which is an attractive option for some patients.2o 
The Catholic teaching with regard to ectopic pregnancy places the 
life of the mother and the life of the unborn child on an equal plane from 
the moment of conception. "No physician or moralist would admit that it is 
lawful to kill the mother in order to save the life of the child; so also it is 
unlawful to kill the child in order to save the life of the mother."24 
Three directives are stated in the Ethical and Religious Directivesfor 
Catholic Health Care Services that apply to ectopic pregnancy. Directive 
47 states: "Operations, treatments, and medications that have as their direct 
purpose the cure of a proportionately serious pathological condition of a 
pregnant woman are permitted when they cannot be safely postponed until 
the unborn child is viable, even if they result in the death of the unborn 
child."3 Directive 48 states: "In case of extra-uterine pregnancy, no 
intervention is morally licit which constitutes a direct abortion."3 What 
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constitutes a direct abortion is stated in Directive 45. "Abortion (that is , the 
directly intended tennination of pregnancy before viability or the directly 
intended destruction of a viable fetus) is never pennitted. Every procedure 
whose sole immediate effect is the termination of pregnancy before 
viability is an abortion, which, in its moral context, includes the interval 
between conception and implantation of the embryo."3 Essentially, the 
directives state that any treatment of an ectopic pregnancy is morally 
permissible as long as it does not cause a direct abortion, even though it 
may result in an indirect abortion. 
How then do we treat the maternal life-threatening condition of an 
ectopic pregnancy while not causing a direct abortion? Catholic ethicists 
have used the principle of double effect to explain the licitness of 
salpingectomy in the treatment of ectopic pregnancy. The principle of 
double effect states: 1) The action, considered by itself and independently 
of its effects, must not be evil; 2) The evil effect must not be the means of 
producing the good effect; 3) The evil effect is sincerely not intended, but 
merely tolerated; 4) There must be a proportionate reason for performing 
the action, in spite of its evil consequences.25 The principle applies to 
ectopic pregnancy in the following way. The removal by salpingectomy of 
a pathologically diseased tube is not an evil action of itself. The death of 
the embryo (the evil effect) does not produce the saving of the mother's life 
(the good effect). The evil effect of the death of the embryo is not intended. 
The life-saving procedure for the mother is proportionate to the loss of the 
embryo. On the other hand, salpingostomy and methotrexate have been 
seen as direct attacks on the embryo, and thus have not been viewed as licit 
treatments. 
Recent Debate on Salpingostomy and Methotrexate 
Recently, a debate has surfaced in the Catholic ethical literature over 
whether salpingostomy and methotrexate can be legitimately used in the 
treatment of ectopic pregnancy. Rev. Albert Moraczewski in the June and 
August 1996 issues of Ethics and Medics gave arguments in favor of the 
legitimacy of salpingosotmy and methotrexate in the treatment of ectopic 
pregnancy.26.27 His arguments state that both procedures essentially act by 
causing an indirect abortion, which if true would be morally acceptable 
options. His argument in favor of salpingostomy states that "to remove the 
pathological tissue in such a manner that part of the tubal wall remains."26 
Rev. Moraczewski is essentially arguing that a salpingostomy is actually 
more of a "micro" partial salpingectomy. "This maneuver extracts a sizable 
amount of damaged tubal tissue ... the embryo proper is also removed."26 
This argument does not apply for the following reasons. First, Stock27 in 
his study of 110 tubal gestations found that growth of the ectopic occurs in 
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mostly an intra-luminal location. In a salpingostomy, the incision is made 
into the tubal lumen, and the ectopic gestation is grasped and usually easily 
expressed out of the lumen, and "care should be taken to avoid trauma to 
the mucosa."4 The maneuver is intended to remove only the ectopic 
gestation, not a "sizable" amount of the tube. Also, salpingostomy works 
because trophoblastic tissue has a loose "attachment" to maternal tissue 
during the first trimester. True "attachment" to maternal tissue actually 
occurs only in the second trimester. 28 The salpingostomy procedure 
essentially only removes the ectopic pregnancy itself, not damaged tubal 
tissue. 
Rev. Moraczewski's argument in favor of the use of methotrexate 
basically states that the intention is to "stop the destructive action of the 
trophoblastic cells," with the unintended effect being the death of the 
embryo.29 The trophoblastic layer (the future placenta) of the embryo is the 
largest functioning organ of the embryo, and remains so until delivery of 
the infant. The trophoblast is just as integral to the life of the embryo as the 
heart is at this time. A direct attack on the trophoblast with methotrexate 
would be equivalent to a direct attack on the heart with potassium chloride. 
Dr. William May, in the March 1998 issue of Ethics and Medics , 
gave arguments against the use of salpingostomy and methotrexate, stating 
that they would constitute a direct abortion. Dr. Eugene Diamond, in the 
August, 1999 issue of the Linacre Quarterly, gives an excellent paper on 
the topic of ectopic pregnancy, and also sides against the use of 
salpingostomy and methotrexate. 
Salpingostomy and methotrexate are interventions which constitute a 
direct abortion, but only when a living embryo is present inside the 
trophoblast. If an embryo never develops or has developed but is now 
"dead," then salpingostomy and methotrexate would constitute licit means 
of treatment of ectopic pregnancy. In order to understand this concept 
better, a review of basic embryology is necessary, as well as a concept of 
what constitutes human death before heart activity is present in the embryo. 
Fertilization of the ovum by the sperm usually occurs in the 
ampullary portion of the fallopian tube. 3D The whole process of 
fertilization, with the combining of the chromosomal material , takes about 
twenty-four hours to complete.30 
This one cell human life is called the zygote. 3D This zygote begins to 
divide into daughter cells called blastomeres, shortly after fertilization is 
completed. Over the next two to three days, while being propelled through 
the fallopian tube by ciliary action and peristalsis, the blastomeres continue 
to divide.3D Up to the eight to sixteen cell stages, all the blastomeres are 
totipotential , that is that each one is capable of forming an entire new 
human life, as in the case of monozygotic twins. 
200 Linacre Quarterly 
When the cells number twelve to fifteen , the name morula is used.3D 
The morula reaches the uterus on about day three or four after 
fertilization. 3D A fluid-filled cavity begins to form in the morula, causing 
the blastomeres to form into an outer cell mass and an inner cell mass .3D 
The outer cell mass or trophoblast will form the chorion and future 
placenta. 3D The blastomeres of the inner cell mass will give rise to the body 
structure, the amnion, and the yolk sac. 3D This is a very important stage of 
differentiation, which will be expanded upon later. The bl astocyst free-
floats in the uterine cavity for the next three days, continuing to grow and 
divide, slowly shedding the acellul ar covering called the zona pellucida. 30 
By the sixth day after fertilization , the outer layer of the trophoblast 
beg ins to implant into the uterine cavity. 30 The total implantation process 
into the endometrial lining takes until the twelfth to thirteenth day after 
fertilization. 3D By day fourteen , the primary chorionic villi start to develop 
and the entire blastocyst measures about 3-4 millimeters. 3D.3 1 Rapid growth 
of the trophoblast and the body of the embryo occurs now so that by post-
conception day twenty-one, the embryonic body measures about 1.5-3.0 
millimeters and the chorionic sac measures about 4-5 mm .31 By post-
conception days twenty-one to twenty-two, embryonic cardiac activity is 
present,3D and can be detectable by trans-vaginal ultrasound almost as early 
as it appears. 32 By the twenty-e ighth day after conception (s ix weeks si nce 
the first day of the last menstrual period on a twenty-eight day cycle), the 
embryonic body measures 4-6 millimeters in size and the chorionic sac 
measures 1.5 centimeters .32 The embryonic body now has visible upper 
and lower limb buds, otic pits (future ears) and lens placodes (future lenses 
of the eye) are also visible. 3D The embryonic body and trophoblast continue 
to grow rapidly, and by the end of the e ighth week all major organ systems 
have formed. 3D At the beginning of the ninth week, the fetal period starts. 
Human Life is Now Present 
Given this very brief overview of embryology, it is important to 
di scuss what constitutes human life and human death before the initi ation 
of embryonic cardiac activity. Human life is present at the moment of 
conception when the zygote is formed, and continues as long as the zygote 
is alive. Human life continues to be present in the morula and blastomere 
stage of development as long as any of the totipotential blastomeres are 
alive, since each can develop into a human being (as in twins). When the 
blastocycst forms, an impOltant differentiation takes place, the creation of 
the inner and outer cell masses. Once this division takes place, an 
outwardly visible organizational structure is made (although it is inwardly 
present from the moment of conception). The inner cell mass contains the 
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cells that develop into the body structure. The outer cell mass or 
trophoblast are the cells which form the future placenta. 
The terminology in this area is sometimes very confusing because 
the term "embryo" can refer to the entire entity(inner and outer cell 
masses) or it can refer to only the embryonic body structure. For purposes 
of this paper, after differentiation into the inner and outer cell masses, I will 
refer to the body structure as the embryonic body, or sometimes as just the 
embryo. 
A hierarchy of the parts is now made, with the embryonic body of the 
inner cell mass being the central part, and all the other structures being 
"organs" of the embryonic body. After the point of division into the outer 
and inner cell masses, human life is present as long as the embryonic body 
develops and continues to grow. If the inner cell mass does not form, or 
forms but stops growing and degenerates, then human life is no longer 
present. 
Failure of the development of the inner cell mass with continued 
growth of the outer cell mass (trophoblast) leads to the clinical entity of a 
"blighted ovum", now called an anembryonic pregnancy. Essentially, it is 
an empty gestational sac, without embryonic body development. The inner 
cell mass for some reason does not develop, while the more resilient outer 
cell mass (trophoblast) does. Newer research in this area shows that total 
failure of any formation of the inner cell mass cells is probably not exactly 
the case. The cells of the inner cell mass do develop for a short time, but 
then stop and degenerate,33 while the trophoblastic tissue continues growth 
for a variable length of time. This is an important concept, because it has 
implications in ectopic pregnancy. 
In a tubal pregnancy, implantation of the blastocycst occurs with the 
invasion of the inner tubal mucosa by the trophoblast. As the ectopic 
grows, there is distention of the fallopian tube, and eventual erosion into 
the arteries of the fallopian tube. The distention of the tube and/or the 
bleeding causes the symptoms of pain. 
Yet unlike the normal embryological development present with an 
intrauterine pregnancy, an ectopic pregnancy very often lacks an embryo.34 
In a review of the prospectively done pathological studies of ectopic 
pregnancy in the literature, an embryo detection rate of only 14-39% was 
reported.35,36,37.38.39 The majority of ectopics only contain an empty 
chorionic sac, disorganized trophoblastic tissue, or hemorrhage without 
identifiable tissue. In the largest of these studies, Poland et al.35 found only 
58 cases which contained an embryo or fetus out of 411 ectopic specimens 
(14%). DiMarchi et a1. 36 found 20 out of 131 cases (15%) to have an 
embryo present. If the numbers from all the studies are combined, 117 out 
of 656 (17)8%) contained an embryo or fetus. Emmrich and Kopping,40 in 
a study of 329 tubal pregnancies, found changes in the trophoblastic villi 
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that were consistent with blighted ovum or transition to blighted ovum in 
84.5% of cases. They suggest that the unfavorable conditions for nidation 
in the fallopian tube have a decisive role in the embryo failing to develop in 
ectopic pregnancies. 
Based on these findings, most ectopic pregnancies have had 
embryonic death occur. If embryonic death is present, then any treatment 
modality can be used, including salpingostomy and methotrexate. The 
criteria for making the diagnosis of embryonic death in ectopic pregnancy 
have not been previously defined or well studied (other than lack of cardiac 
activity in an identifiable embryo). Can we reliably diagnose which ectopic 
pregnancies have a living embryo and which have had embryonic death? 
Current Diagnostic Capabilities 
The following is an assessment of the current diagnostic capabilities. 
Some physicians may disagree with this assessment. In utilizing the current 
diagnostic studies of sensitive B-HCG assays, trans-vaginal ultrasound, 
and progesterone assays, ectopic pregnancies can be divided into one of 
three categories: 1) embryonic life is present; 2) embryonic death has 
occurred; and 3) unable to determine if embryonic life or death is present. 
First let us consider the case where embryonic life is present based 
upon current diagnostic studies. Cardiac activity visualized by ultrasound 
in an ectopic pregnancy is a definite sign of embryonic life, thus human life 
is present. Cardiac activity is reported to be visualized by trans-vaginal 
ultrasound in 15-28% of patients with an ectopic pregnancy.41,42 Brown and 
Doubilet43 in a meta-analysis showed that an adnexal embryo with a 
heartbeat can be seen in 99 of 492 patients (20.1 %) with a known ectopic 
pregnancy. These numbers closely correlate with the probability of finding 
an embryo in ectopic pregnancies based on the pathological studies. If a 
living embryo is present outside the uterus, it will be most likely found by 
trans-vaginal ultrasound. 
Second, let us consider the case where embryonic death has occurred 
based on current diagnostic studies. When the diagnosis of ectopic 
pregnancy (the diagnosis of ectopic pregnancy is a topic in itself and will 
not be addressed in detail) is highly suspected based on the clinical 
information and embryonic cardiac activity is not seen on trans-vaginal 
ultrasound, the following criterion is evidence that embryonic death has 
occurred: a progesterone level <5 ng/ml and B-HCG levels that are not 
appropriately rising «25% rise over two days). 
McCord et al.lO retrospectively studied 3,674 pregnancies and divided 
the patients into three pregnancy outcomes: viable intrauterine pregnancy, 
spontaneous abortion, and ectopic pregnancy. They found that a viable 
intrauterine pregnancy occurred in only 2 of 1,279 patients (0.16%) with 
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serum progesterone level <5 ng/ml , but both of these patients had normally 
ri sing ~-HCG levels. Hahlin+l found that no normal intrauterine pregnancy 
had both a progesterone level of <30 nmolll (9.4 ng/ml) and an abnormal 
increase in ~-HCG, whereas 72% of ectopic pregnancies and 81% of 
spontaneous abortions had both of these laboratory results. The other 28% 
of ectopic pregnancies are those with a higher progesterone level and/or 
normally increasing ~-HCG levels. These are the pregnancies that are most 
likely to contain a living and growing embryo. Ectopic pregnancies with a 
li ving embryo have a higher mean ~-HCG level 36 and thus must have a 
functioning embryo-trophoblast unit. To also support this concept, Johnson 
et al.45 postulate that the embryo (apart from the trophoblast) plays an 
essential role in inducing the production of progesterone by the ovary 
which is superimposed on the luteotrophic effect of ~-HCG from the 
trophoblast. Kada et al. -l6 studied ~-HCG levels in early pregnancy in order 
to find if the slope of the log of ~-HCG concentrations over time can 
di stinguish between normal intrauterine pregnancies, ectopic pregnancies 
and spontaneous abortions. The slope of the logarithm of ~-HCG of all 
normal pregnancies was greater >0.05 (25% increase over 2 days), and 
42% of ectopic pregnancies have slopes below this level. Stewart et al.47 
performed a similar type of study, all of their normal intra-uterine 
pregnancies had slopes above 0.10% (60% rise over two days), and 57% of 
ectopic pregnancies have slopes below this level. In essence, ectopic 
pregnancies that have a living embryo present, behave similarly in 
biochemical terms to normal intra-uterine pregnancies. Ectopic pregnancies 
that had embryonic death occur, act biochemically similar to spontaneous 
abortions. The progesterone level of <5 ng/ml (instead of 9.4 ng/ml) and a 
~-HCG increase less than 25 % over two days (instead of 60%)were used 
here because this errs on the side of caution. This cliterion excludes those 
ectopic pregnancies in which embryonic life is still possible. 
This again is not a stand-alone criterion; this is only useful when the 
clinical information makes the diagnosis of ectopic pregnancy very likely. 
Also, the diagnosis of embryonic death may be made with criteria other 
than the one listed above. A conscientious physician may diagnose 
embryonic death with the available clinical information of the particular 
patient, but this would need to be done on a case-by-case basis. Individual 
physicians and hospitals may vary with regard to the reliability of the 
diagnostic tests just stated. 
Third, let us consider the case where it is uncertain whether 
embryonic life or death is present. When the clinical information cannot 
determine that embryonic death has OCCUlTed, waiting and further 
diagnostic studies would be indicated. If there is doubt whether embryonic 
death has occurred, then it should be assumed that embryonic life is still 
present. 
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The treatment options for ectopic pregnancy should be based on the 
presence or absence of embryonic life. If embryonic life is present, total 
salpingectomy or partial salpingectomy with tubal re-anastomosis are the 
only licit options available. Salpingectomy (partial or total) would be 
permissible using the principle of double-effect, and probably makes the 
most sense surgically as well. The growth of an ectopic pregnancy with 
embryonic cardiac activity probably causes a much more substantial 
degree of tubal damage as compared with an anembryonic ectopic/ so 
tubal integrity is severely impaired and risk of future ectopic greatly 
increased. Salpingectomy in these cases would be the optimum treatment. 
Transplantation of the viable ectopic pregnancy into the uterus would be 
the best solution, but has had documented success only two times in the 
medical literature, as ofthis writing. The limited success of transplantation 
may be secondary to the lack of a living embryo present in the majority of 
ectopic pregnancies. If embryonic death is present, salpingectomy, 
salpingostomy, or methotrexate are all options for the patient, with the 
decision to be based on the clinical judgment of the physician. The growth 
of an ectopic with very early embryonic demise probably causes much less 
tubal damage as compared with a viable ectopic/ so salpingostomy or 
methotrexate may prove to be adequate treatment options that also allow 
enhanced future fertility. In cases of doubt whether a living embryo is 
present, salpingectomy would be the only licit option available. 
In conclusion, ectopic pregnancy is an unfortunate event that is 
increasing in frequency. In most cases of ectopic pregnancy, an embryo is 
not present. In cases where a living embryo is found or we are unable to 
determine if a living embryo is present, salpingectomy is the procedure to 
be performed. If embryonic death is diagnosed, then licit treatments are 
salpingectomy, salpingostomy, or methotrexate. 
Transplantation of a living embryo into the uterus is the ideal 
procedure, and if perfected, would be a tremendous breakthrough in the 
treatment of ectopic pregnancy. Hopefully, success will come soon. 
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